NAI for Sepsis With Persistent Lymphopenia
← catalyst calendarNCT07578558 · readout in 348 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
50estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-06 | estimated | When the study began enrolling |
| Primary completion | 2027-08-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sepsis
- Septic Shock
- Lymphopenia
- Immunosuppression
- Critical Illness
Interventions
- Drug: Nogapendekin alfa inbakicept (NAI) — also filed as N-803, ANKTIVA, Nogapendekin alfa-inbakicept
- Other: Standard of Care (SOC)
Primary outcome
what the primary-completion date above is the date OF28-day all-cause mortality rate
measured 28 days
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed